gross profit vs pcp ytd gross margin
pcp myx report group revenu vs pcp four month
driven continu competit gener product
specialti brand divis exclud fx benefit estim
revenu declin vs pcp weaker product mix
gener stock obsolesc gross margin declin
pcp rate myx gross profit result impli
run-rat cs estim
specialti brand revenu declin high margin
specialti brand divis saw declin revenu vs pcp
month exclud fx benefit estim revenu declin
vs pcp sorilux doryx impact new product
launch includ new tetracyclin antibiot treat acn despit
myx mention seen improv trend octob
anticip signific improv product go forward
lexett solid ramp-up script vs
tolsura yet show signific script volum ytd
forecast flat specialti revenu
forecast ebitda vs pcp myx
strong pipelin new product earn benefit
forecast ebitda ebitda flat vs pcp driven
continu competit key gener product liothyronin dofetilid
capsul methylphenid gener acticl weak specialti
opex save achiev ytd larg enough off-set
earn declin
decreas ebitda estim dcf
deriv target price fall per share myx
three core drug drive earn growth view market
need evid success execut product launch
factor full earn benefit drug valuat
particularli given challeng short-term earn profil continu
catalysts/risk fda approv product launch result
valuat metric
chang previou ep
price month
total return forecast perspect
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
 asx close
spot exchang rate
price book
return equiti
return asset
return invest cap
net debt ebitda
capital-expenditure sale
capital-expenditure depr
price rate neutral target price analyst gretel janu
profit tax
profit tax
unusu item tax
chang work capit
cash non-cash item
movement cash/equival
myx provid trade updat end octob gener
specialti brand divis perform expect despit signific fx benefit
group revenu yoy impli run rate
vs cse includ estim fx benefit
gross profit yoy impli run rate
estim weaker product mix growth specialti brand led
gross margin weaken vs pcp
gener product divis sale impact liothyronin
dofetilid competit usd term estim sale declin
manag explicitli call addit competit script data show
competit capsul methylphenid gener acticl
also inventori obsolesc gener impact margin
believ launch ramp gener fentora enough off-set declin
specialti brand sale flat lower expect doryx
sorilux sale prior year off-set lexett tolsura usd term
sale stronger estim benefit
addit analyt servic formul develop revenu usd term
estim sale expect five commerci manufactur
client three expect launch greenvil manufactur
product
mpi sale expect
myx continu expect launch continu target
fda gener nuvar approv
follow trade updat make number chang estim
result downgrad ebitda estim averag
downgrad ep forecast period figur chang includ
decreas gener revenu estim due weaker revenu result ytd
forecast sale usd term forecast less
contribut new product develop outer year assum greater
product price eros reduc gross margin assumpt continu stock
charl martineau pm univers toronto decreas specialti brand revenu due weak doryx sorilux
assum flat growth sorilux also assum slower ramp-up sale
tolsura forecast sale usd term
updat estim shown tabl
good sold
depreci asset
amortis
profit tax
figur new competit liothyronin
figur dofetilid
bloomberg profession servic credit suiss estim
figur new competit
bloomberg profession servic credit suiss estim
figur methylphenid
bloomberg profession servic credit suiss estim
figur growth start weaken sorilux
sorilux fabior weekli prescript
bloomberg profession servic credit suiss estim
bloomberg profession servic credit suiss estim
bloomberg profession servic credit suiss estim
figur gener product largest segment
revenu contribut divis
gross profit contribut divis mn
figur gross margin weaker
chart compani data credit suiss estim
new total return forecast perspect chart help visual credit suiss consensu view compani return within
context forecast risk histor trade pattern
volatil calcul annualis standard deviat weekli total return seri past month illustr variabl
stock return word risk way think one would rather take forecast return stock volatil
stock volatil shade area show one standard deviat rang base past month volatil statist
term make number brave assumpt probabl share price end insid rang month
hi-lo maximum minimum daili close price past week often handi know price momentum especi
stock trade close high low stock trade close peak momentum stock
consensu consensu suppli thomson reuter survey sell side research analyst collect dozen data
point ep dp sale target price roe mean averag target return shade area around mean
repres rang estim lowest highest estim aid visualis number import factor rang
analyst estim credit suiss estim stock sit rel consensu share price rel consensu
mean consensu rang target
return calcul capit gain plu forecast dividend yield net next month cs tgt use credit suiss
target price credit suiss forecast forward dividend gross frank consensu mean rang use
consensu target price consensu dividend forecast month forward
compani mention price
